Login to Your Account

One week/three deals for Santaris’ RNA-targeting technology

By Nuala Moran
Staff Writer

Friday, January 10, 2014
LONDON – It’s been a busy first week on the job for the new CEO of Santaris Pharma A/S, Donald deBethizy, as a trio of deals was announced, with Roche AG, Glaxosmithkline plc and Isarna Therapeutics GmbH, around the company’s RNA-targeting technology.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription